FOSUN HEALTH Logo

Ovarian Cancer Diagnosis

catalogue

Ovarian Cancer Diagnosis

Ovarian Cancer Diagnosis

Ovarian cancer is diagnosed in two movements: imaging and markers raise the suspicion and map the disease, and surgery — in fit women with operable disease — delivers both the tissue diagnosis and the FIGO stage in the same operation.

Ultrasound: the first test

Pelvic and transvaginal ultrasound is where almost every ovarian evaluation begins, and it answers the questions that decide what happens next: is there a mass, is it ovarian, and what does it look like? Modern ultrasound characterises a mass by its internal architecture — simple cyst, complex mass with solid areas, septations, blood-flow pattern — and simple cysts in menstruating women are common findings that need no surgery.

What ultrasound cannot do is stage the disease: it sees the ovary well and the upper abdomen poorly. Its role is to decide whether the mass is worth a CT — and, together with CA-125, whether the patient should be referred to a gynaecological oncology centre rather than a general surgical service, a step that measurably changes how complete the eventual operation is.

CA-125 and HE4: what they can do

CA-125 is a blood protein that rises in many ovarian cancers — and in many benign conditions. Its honest job description: in a woman with a known mass, a high CA-125 raises suspicion and supports referral to an oncology centre; in a woman without a mass, it diagnoses nothing. After treatment it becomes a trend to follow. HE4, often paired with CA-125 in a combined score (ROMA), adds a little discrimination between benign and malignant masses.

Two usage errors to avoid. First, a normal CA-125 does not exclude ovarian cancer — a proportion of early and clear cell tumours do not raise it. Second, an elevated CA-125 without a mass is a prompt for imaging and follow-up, not for a cancer diagnosis. The marker is part of a judgement; it is not the judgement.

CT and the resectability map

CT of chest, abdomen and pelvis is the staging map. It answers two distinct questions. The first is spread: peritoneal deposits, omental cake, lymph nodes, pleural effusion, liver or spleen involvement. The second — the one that shapes the whole pathway — is resectability: whether the disease visible on CT is the kind a surgeon can remove completely in one operation. Diffuse small-bowel surface disease, disease at the root of the mesentery, or extensive diaphragmatic involvement argue that surgery should follow chemotherapy rather than precede it.

This resectability assessment is a joint reading by imaging and surgery, and it is worth doing before travel rather than after: it is the finding that decides whether a patient arrives for an operation or for chemotherapy. MRI is occasionally used for characterising an indeterminate mass; PET-CT adds information in recurrence rather than in primary staging.

Surgical staging

FIGO staging in ovarian cancer is surgical by design: the stage is assigned from peritoneal washings, biopsies of the peritoneal surfaces, omentectomy, lymph node sampling and the histology of what is removed. Scans miss deposits smaller than a centimetre; the operation does not. For a woman whose imaging suggests operable disease, the first operation is both the biopsy and the staging procedure — which is why it is planned as a cancer operation from the start, by a gynaecological oncology team, and not begun as a simple cyst removal that turns into something larger.

Where disease is clearly not resectable, or the patient is not fit, the sequence inverts: tissue is obtained by biopsy, chemotherapy starts, and surgery follows as interval debulking. Both routes end with the same information; the order is chosen to protect the completeness of the operation.

Histology and the type

The pathology report does two jobs. It assigns the type — high-grade serous, clear cell, endometrioid, mucinous, germ cell, stromal — which sets the protocol. And it grades the behaviour: high-grade serous and low-grade serous are different diseases with different chemotherapy sensitivity despite similar names. Immunohistochemistry and molecular tests on the specimen complete the picture, and the BRCA/HRD status is tested on this tissue.

For international patients the practical translation: the pathology report and, where possible, the paraffin blocks are among the most valuable items in any file sent abroad — the type decides the protocol, and the blocks allow BRCA and HRD testing without a repeat procedure.

Bringing it into one plan

Diagnosis in this disease is not complete until four documents exist: the ultrasound and CT reports with the imaging itself, the CA-125 (and HE4) values, the pathology or cytology report where tissue has been obtained, and the resectability assessment derived from the CT. The plan then answers, in order: is this operable upfront, or does chemotherapy come first; which protocol fits the type; and has germline BRCA testing been arranged.

For international patients, the file that allows a gynaecological oncology MDT to answer within 48 hours is exactly those four items. The most commonly missing is the imaging itself — discs or links rather than reports — and it is the item on which the surgery-versus-chemotherapy decision turns.

Frequently Asked Questions

I have an ovarian cyst — is it cancer?

Most are not, and the ultrasound appearance is what tells them apart. Simple cysts — thin-walled, fluid-filled — are common in menstruating women and usually resolve on their own; complex masses with solid areas, septations and internal blood flow need closer assessment. Menopause changes the threshold: a cyst in a postmenopausal woman is taken more seriously. The assessment is an ultrasound with CA-125 in context, and follow-up imaging at a defined interval where the appearance is indeterminate — not immediate surgery for every cyst.

Why is the tissue diagnosis made during surgery rather than before?

Because in fit women with operable disease, the operation that confirms the diagnosis is the same operation that treats the disease — and percutaneous needle biopsy of a suspected early ovarian cancer risks seeding tumour cells along the track. When disease is clearly advanced or unresectable, the sequence inverts and a biopsy comes first. The rule follows resectability, not habit.

What is a resectability assessment?

It is the joint imaging-and-surgery judgement of whether all visible disease can be removed in one operation — the question that decides whether surgery comes first or chemotherapy does. It is read from the CT with the surgeon's own examination, and it is the finding on which the whole sequence turns. An operation that starts before this question is answered is the error the pathway exists to prevent.

Should BRCA testing be done before or after treatment starts?

Arrange it at diagnosis. The result determines eligibility for PARP-inhibitor maintenance after chemotherapy, and the choice of first-line additions in defined situations; having it ready means the maintenance decision can be made the moment chemotherapy ends rather than weeks later. Testing uses blood (germline) and tumour tissue, and a germline result also opens testing and risk assessment for relatives.

Patient Stories

Stories from our ovarian cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Have imaging or a mass already found, and deciding where to go?

Upload the ultrasound and CT with the imaging itself, CA-125 and HE4 values, and any pathology. Our gynaecological oncology MDT will confirm the resectability assessment and what should come first — a written assessment within 48 hours.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*